Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: Stage II Cutaneous T-cell Non-Hodgkin Lymphoma
Stage I Cutaneous T-cell Non-Hodgkin Lymphoma
Stage IA Mycosis Fungoides/Sezary Syndrome
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Recurrent Mycosis Fungoides/Sezary Syndrome
Stage IB Mycosis Fungoides/Sezary Syndrome
Stage IIA Mycosis Fungoides/Sezary Syndrome

Interventions: Drug: silicon phthalocyanine 4
Drug: photodynamic therapy
Other: pharmacological study
Other: laboratory biomarker analysis

Brief Summary: This phase I trial studies the side effects and best dose of silicon phthalocyanine 4 and photodynamic therapy in treating patients with stage IA-IIA cutaneous T-cell non-Hodgkin lymphoma. Photodynamic therapy (PDT) uses a drug, silicon phthalocyanine 4, that becomes active when it is exposed to a certain kind of light. When the drug is active, cancer cells are killed. This may be effective against cutaneous T-cell non-Hodgkin lymphoma.

Funding Source - FDA OOPD

Detailed Description: PRIMARY OBJECTIVES:

I. Determine the safety and maximum tolerated dose (MTD) that can be utilized for a single treatment of Pc 4-PDT (silicon phthalocyanine 4 photo dynamic therapy) on subjects with mycosis fungoides (MF)/cutaneous T-cell lymphoma (CTCL) stage IA-IIA, by evaluating an accelerated dose escalation protocol consisting of a single exposure to PDT using topically-applied Pc 4 and visible light at a wavelength of 675 nm, followed by assessment of skin biopsies to analyze cellular and molecular changes induced by Pc 4-PDT. (Cohort I)

II. Determine safety and tolerability of repeated light (PDT) exposures after a single application of Pc 4 to a MF/CTCL plaque, using topically-applied Pc 4 and visible light at a wavelength of 675nm, followed by assessment of skin biopsies to analyze cellular and molecular changes induced by Pc 4-PDT. (Cohort II)

III. Identification of targets for assessment of efficacy to assist in planning for a Phase II study.

OUTLINE: This is a dose-escalation study.

Patients receive silicon phthalocyanine 4 topically and then undergo PDT.

After completion of study treatment, patients are followed up at 24 hours, 1 week, 2 weeks, and 30 days.

Recruitment & Eligibility

Inclusion Criteria

Diagnosed with early stage MF (CTCL stage IA-IIA)
Has at least 2 evaluable plaques
Has been off systemic therapies for at least 4 weeks
Has been off topical therapies for at least 2 weeks
Has been off phototherapies for at least 2 weeks
All skin photo-types will be included
Subjects must have the ability to understand and the willingness to sign a written informed consent form
Women of child-bearing potential must agree to utilize a birth control which results in a failure rate of less that 1% per year during the study; accepted forms of birth control for this study include: injections such as Depo-Provera and Lunelle, implants such as Norplant, and intra-uterine devices
Sexually active males must agree to use a medically acceptable form of birth control for the duration of the study and for at least 3 months after the last dose of the study medication; appropriate birth control methods are using a condom with a spermicide or surgical sterilization

Exclusion Criteria

Active history of photosensitivity (e.g. xeroderma pigmentosum, lupus erythematosus, porphyria, severe polymorphous light eruption, solar urticaria)
Any medical condition that could be aggravated or may cause extreme discomfort during the study period
Lesions only on the face, scalp or other sites that would make biopsies not cosmetically acceptable
Women of childbearing potential who are pregnant or attempting to become pregnant are excluded from this study
History of allergic reactions attributed to compounds of similar chemical or biologic composition to silicon phthalocyanine (Pc 4) or other agents used in this study
Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Arm && Interventions

Group	Intervention	Description
Treatment (silicon phthalocyanine 4 and PDT)	silicon phthalocyanine 4	Patients receive silicon phthalocyanine 4 topically and then undergo PDT.
Treatment (silicon phthalocyanine 4 and PDT)	laboratory biomarker analysis	Patients receive silicon phthalocyanine 4 topically and then undergo PDT.
Treatment (silicon phthalocyanine 4 and PDT)	pharmacological study	Patients receive silicon phthalocyanine 4 topically and then undergo PDT.
Treatment (silicon phthalocyanine 4 and PDT)	photodynamic therapy	Patients receive silicon phthalocyanine 4 topically and then undergo PDT.

Primary Outcome Measures

Name	Time	Method
MTD of Photodynamic Therapy	Up to 30 days	Defined as the dose immediately below the dose in which 2 or more of 6 patients experience a grade 4 toxicity assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
MTD of Silicon Phthalocyanine 4 Defined as the Dose Immediately Below the Dose in Which 2 or More of 6 Patients Experience a Grade 4 Toxicity Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0	Up to 30 days

Secondary Outcome Measures

Name	Time	Method

Locations (1): University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
🇺🇸
Cleveland, Ohio, United States